3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Melanoma
33
Thyroid Neoplasms
9
Neoplasms
8
Thyroid Carcinoma, Anaplastic
7
Thyroid Cancer, Papillary
4
Neoplasm Metastasis
4
Multiple Myeloma
4
Colorectal Neoplasms
4
Ameloblastoma
4
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Skin Neoplasms
2
Lymphoma, Non-Hodgkin
2
Glioma
2
Adenocarcinoma, Follicular
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Thyroid cancer, follicular
1
Thyroid cancer, Hurthle cell
1
Thrombocytosis
1
Spinocerebellar Degenerations
1
Solid Tumor
1
Sexual Dysfunction, Physiological
1
Rare Malignant Neoplasm
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Interventions
Rituximab
5
fludarabine
4
Tacrolimus
4
Epoetin Alfa
4
Cyclophosphamide
4
Busulfan
4
Darbepoetin alfa
3
Alemtuzumab
3
fludarabine phosphate
2
entrectinib
2
atezolizumab
2
alectinib
2
Thiotepa
2
Therapeutics
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Methotrexate
2
Etoposide
2
Early Intervention, Educational
2
Cytarabine
2
Bortezomib
2
Antilymphocyte Serum
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
venetoclax
1
trametinib
1
tirbanibulin
1
sargramostim
1
plerixafor
1
phenethyl isothiocyanate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoproliferative Disorders
×
dabrafenib
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled